Biocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Investor Meeting21-09-2021
21-09-2021
Can Serum deal provide a booster dose to Biocon's target price?
The Serum alliance would give Biocon Biologics' access to 100 million doses of vaccines per annum for 15 years with commercialisation rights, including that of Covid-19 vaccines, for global markets.20-09-2021
Serum-Biocon alliance to make India a global vaccine manufacturing powerhouse: SII
Biocon Biologics Limited, a subsidiary of Biocon, on Thursday announced a strategic alliance with Serum Institute Life Sciences, a subsidiary of SII17-09-2021
Biocon Conference Call: Biocon Biologics and Serum Institute Merger Announcement
Conference Call with Management from Biocon (Kiran Mazumdar Shaw) and Serum Institute (Adar Poonawalla) on the strategic alliance between Biocon Biologics and Serum Institute subsidiary Covidshield Technologies. Listen to the full transcript.17-09-2021
Biocon-Serum alliance to build a global biotech powerhouse, say Kiran Mazumdar-Shaw, Adar Poonawalla
Speaking at a press conference today, they said the synergistic future oriented deal will help growth of both companies17-09-2021
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Biocon Biologics and Serum Institute Life Sciences Announce Strategic Alliance16-09-2021
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Investor Meeting15-09-2021
Biocon inks patent litigation settlement pact with Celgene
Biocon shares were trading 0.45% up on BSE08-09-2021
India to take 9 more months for full vaccination; avoid congregations: Shaw
India has done a tremendous job on the vaccination drive but it will take at least nine more months to fully vaccinate all adults, Biocon Chairperson Kiran Mazumdar Shaw said on Tuesday.07-09-2021